FDA Asks Small Dispensers to Report Drug Tracking Info
Published Date: 11/21/2025
Notice
Summary
The FDA is asking small medicine dispensers to share info about how they track prescription drugs to keep the supply chain safe and secure. This new info collection is part of a law that helps trace medicines electronically, making sure they’re real and safe. Comments on this plan are open until December 22, 2025, and it could affect small dispensers’ paperwork and processes.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
Small dispensers asked to complete DSCSA assessment
If you run a medicine dispenser with 25 or fewer full‑time employees, FDA is asking you (or an entity representing you) to answer an assessment questionnaire about electronic package‑level drug tracing. FDA estimates 922 respondents will complete the questionnaire, that it will take about 2 hours to compile answers and respond, and that respondents will have 45 days to complete the questionnaire after the link is posted.
Required coordination with third‑party partners
FDA expects respondents to coordinate with third‑party entities (like solution providers, wholesale distributors, or consultants). For screener questions, FDA estimates 692 respondents will make 1,384 disclosures at about 0.1 hour each; for full assessment responses, FDA estimates 461 respondents will coordinate with two partners at about 2 hours per coordination.
Large email outreach to industry contacts
FDA plans to send 18,430 invitation emails to firms on its industry stakeholder list asking them to consider the assessment. The agency estimates it will take about 0.1 hour (6 minutes) to read each invitation and decide whether to participate.
Recordkeeping recommendation for one year
FDA recommends that respondents keep records generated while answering the assessment and retain questionnaire responses for at least 1 year after FDA publishes its final report. FDA estimates recordkeeping will take about 0.5 hour per responding entity.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17659, Rahim Shafa; Denial of Hearing; Final Debarment Order
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Rahim Shafa (Dr. Shafa) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Dr. Shafa from providing services in any capacity to a person that has an approved or pending drug product application and debarring Dr. Shafa for 20 years from importing or offering for import any drug into the United States. FDA bases this order on the findings that Dr. Shafa was convicted of multiple felonies under Federal law that relate to the regulation of any drug product under the FD&C Act and the importation into the United States of any drug or controlled substance under the FD&C Act. FDA provided notice to Dr. Shafa of the proposed debarment and an opportunity to request a hearing. Dr. Shafa submitted a request for a hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
2026-17676, Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection pertaining to the registration of human drug compounding outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and associated fees.
2026-17598, Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups and Interviews as Used by the Food and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the generic collection of focus group information as used by FDA for all FDA-regulated products.
Previous / Next Documents
Previous: 2025-20642, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Student Assistance General Provisions-Student Right To Know (SRK)
The Department of Education wants to keep collecting info about the Student Right To Know rules without changing anything. This affects schools and governments who share important student data, and they’re asking for public comments by December 22, 2025. No new costs or changes, just a smooth extension to keep things running on time.
Next: 2025-20644, Agency Information Collection Activity: Civil Rights Discrimination Complaint
The Department of Veterans Affairs is updating its Civil Rights Discrimination Complaint form and wants your feedback by January 20, 2026. This affects veterans and others who feel their civil rights were violated by VA staff. The goal is to make the form clearer and easier to use without adding extra hassle or cost.